LCTX: Lineage Cell Therapeutics, Inc. Company Profile & Statistics

About

Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.

Info & Links

CEO

Brian M. Culley

Headquarters

2173 SALK AVENUE, SUITE 200
CARLSBAD, CA 92008, UNITED STATES

Auditor

WithumSmith+Brown, PC

Share holders

358

Employees

Lineage Cell Therapeutics, Inc. Statistics

Valuation Measures

Market Capitalization²

125.20M

Enterprise Value

97.58M

Enterprise Value/EBITDA(ttm)

-4.41

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

17.53

Price to Book(mrq)

2.02

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

94.21%

Operating Margin(ttm)

-230.66%

Profit Margin(ttm)

-292.78%

Return on Equity(ttm)

-30.39%

Return on Invested Capital(ttm)

-30.07%

Return on Assets(ttm)

-19.67%

Income Statement

Revenue(ttm)

8.72M

Revenue Per Share(ttm)

0.05

Gross Profit(ttm)

8.28M

EBITDA(ttm)³

-22.12M

Net Income Available to Common(ttm)

-20.11M

Diluted EPS(ttm)

-0.12

Share Statistics

Beta (5Y Monthly)

1.21

52-Week Change

-35.53%

S&P 500 52-Week Change

18.02%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

188.84M

Dividend Yield

0.00%

Float⁴

168.40M

% Held by Insiders

23.60%

% Held by Institutions

62.47%

Balance Sheet

Total Cash(mrq)

32.71M

Total Cash Per Share(mrq)

0.17

Total Debt(mrq)

134.00K

Total Debt/Equity(mrq)

0.21%

Current Ratio(mrq)

2.48%

Quick Ratio(mrq)

2.48%

Book Value Per Share(mrq)

0.34

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.09

Free Cash Flow(ytd)

-16.95M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

LCTX

Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. Profile